Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly.
https://t.co/2ZLONMncTT
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®.
https://t.co/dtKxhxwCSO
Today at the World Vaccine Congress, our Chief Scientific Officer, Dr Hanneke Schuitemaker will be leading a working group focused on on Prophylactic Enteric Disease Vaccines.
You can also find our team at booth #424 - we hope to see you there!
#WVCUSA
Join us at World Vaccine Congress 2025!
We are delighted that three members of the Valneva team will be sharing their knowledge at various events over the next few days. You can also visit us at booth #424.
Read our press release here: https://t.co/DbCFcGyvLM
#WVCUSA
We're excited to launch our Annual Business Report website!
The website provides insight into Valneva’s mission, financial outlook and serves as a hub for our 2024 annual results resources.
To find out more, visit:
https://t.co/5CyAssLa5z
#AdvancingVaccinesForBetterLives